Skip to main content

HEALWELL AI Participates in Leading-Edge Research on Chronic Kidney Disease Highlighting the Potential of its AI Powered Clinical Co-Pilot

  • HEAWELL AI’s Clinical Co-Pilot technology participated in recently published evidence showing the integration of a highly accurate machine model for Chronic Kidney Disease (“CKD”) progression when paired with Electronic Health Record (“EHR”) linked clinical decision support, improves guideline-recommended testing in patients with CKD.
  • HEALWELL’s subsidiary Khure Health (“Khure”) co-authored an abstract that was published this month in the American Journal of Kidney Diseases, providing evidence of Khure’s Clinical Co-Pilot’s utility to support improved CKD patient care by US Nephrologists.
  • CKD is a major health problem affecting approximately one seventh of the population in North America. In Canada alone, the economic burden of chronic and end-stage kidney disease costs the national healthcare system more than $40 billion per year.
  • WELL Health Technologies Corp. (TSX:WELL) recently launched WELL AI Decision Support (“WAIDS”), its second-generation AI powered physician Co-Pilot powered exclusively by HEAWELL and available to assist thousands of providers within the WELL ecosystem.

TORONTO, May 16, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), a healthcare technology company focused on AI and data science for preventative care, is pleased to announce that it has participated in recently published leading-edge research on Chronic Kidney Disease (“CKD”) in the esteemed American Journal of Kidney Diseases (“AJKD”). HEALWELL’s AI-powered clinical decision support Co-Pilot technology paired with a highly accurate machine model for CKD progression supports US-based Nephrologists to improve guideline recommended testing in CKD patients. This marks a significant validation of the capability of such advanced technology in chronic diseases; an area of particular importance due to the burden of chronic diseases including CKD on the North American population.  HEALWELL’s recently launched second-generation AI Clinical Co-Pilot incorporates similar advanced technology to support physicians with improved patient care.

The American Journal of Kidney Diseases recently published an abstract entitled “Baseline Characteristics and Early Results From The Gemini-Rapa Project: Improving The Quality Of CKD Care With Risk Prediction And Personalized Recommendations”(1), emphasizing how the integration of a highly accurate machine model for CKD progression when paired with Electronic Health Records (“EHR”) linked clinical decision support improves guideline-recommended testing in patients with CKD. This highlights how HEALWELL’s technology can support US specialists in one of the most important chronic disease domains; chronic kidney disease. This abstract(1), co-authored with BAYER LLC US, Renal Associates PA, and Klinrisk Inc. was also presented this week at the National Kidney Foundation meeting in Laguna Beach, California.

Dr. Alexander Dobranowski, CEO of HEALWELL, added, “Chronic diseases are the leading cause of death and disability in Canada and we couldn’t be more excited to publish in the respected American Journal of Kidney Diseases alongside such reputable lead authors, validating the utility of our advanced technology and how it can leverage other key technology in playing a key role in supporting improved chronic disease patient care.”

On May 2, 2024, HEALWELL announced its partner and shareholder, WELL Health Technologies Corp. (TSX:WELL) (“WELL”), launched the second-generation of WELL AI Decision Support (“WAIDS”), its AI-powered physician Co-Pilot powered exclusively by HEAWELL. This technology is now commercially available to the WELL network which consists of thousands of healthcare providers within the WELL ecosystem. For more information on WELL AI Decision support, please visit:

CKD is a major health problem affecting approximately one seventh of the population in North America. In Canada alone, the economic burden of chronic and end-stage kidney disease costs the national healthcare system more than $40 billion(2) per year. According to a Statistics Canada report in 2023 on the Health of Canadians(3), 45.1% of Canadians lived with at least one major chronic disease in 2021 and Canadians with Chronic Kidney Disease comprised 11-13%(4) of the entire population.  


  1. Baseline Characteristics and Early Results from the GEMINI-RAPA Project: Improving the Quality of CKD Care with Risk Prediction and Personalized Recommendations, AJKD, VOLUME 83, ISSUE 4, SUPPLEMENT 2, S87, APRIL 2024,
  2. Source: Statistics Canada,,billion%20per%20year%20in%20Canada.&text=Manns%20et%20al1%20estimated,payments%20for%20patients%20with%20CKD.
  3. Source: Statistics Canada,
  4. Source: National Library of Medicine,,13%25%20of%20the%20population%20globally.

Dr. Alexander Dobranowski
Chief Executive Officer


HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange (the “TSX”) under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit

Forward Looking Statements

Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws, and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as ""improve", "growth", "position", "pushing", "supporting", "advancing" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; trends in customer growth and the adoption of new technologies in the industry; anticipated viewership and impact of the publication; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.

Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated April 1, 2024, which is available under HEALWELL's SEDAR+ profile at The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.

For more information:

Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392 

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.